Outlook of China Biopharmaceutical Outsourcing Market

Transcription

1 中 国 生 物 医 药 外 包 市 场 前 景 分 析 Outlook of China Biopharmaceutical Outsourcing Market JZMed, Inc.

2 Report Description Attracted by the fast growth of the Chinese biopharmaceutical market as well as the thriving of the Chinese biopharmaceutical industry, growing numbers of pharma and biopharma companies large or small around the world have become interested to conduct biologic drug R&D and manufacturing in China in addition to marketing their products in the country. Their entrance and further expansion of their local presence also prompt them to seek services from the local companies to support their local activities. Their demands for various types of supporting services are thus driving up the rapid growth of the Chinese biopharmaceutical outsourcing market. Meanwhile, with the increasing availabilities of funding opportunities from both public and private sources, coupled with the support and encouragement of local government, the Chinese pharma and biopharma companies have been increasing their investment in both R&D and manufacturing of biologics. To effectively accomplish their development goals, a large portion of them are also seeking service supports from local biopharma outsourcing service providers, thus further driving the fast growth of this new Chinese outsourcing market. The report, Outlook of China Biopharmaceutical Outsourcing Market, published by JZMed, Inc, a world renowned market research firm specialized in pharmaceutical and biotechnology industries, has conducted so far the most complete and comprehensive analysis on Chinese biopharmaceutical outsourcing service industry and market. It has revealed the current development state, the available services, and the service capabilities and limitations of the Chinese companies in biopharmaceutical outsourcing, in particular in biologic drug discovery research and biopharmaceutical manufacturing. The report provides readers clear insights of both the current state and the future growth potential of the biopharma outsourcing market in China. It also greatly helps global pharmaceutical and biopharmaceutical companies better understand this Chinese industry, including its current strengths and weaknesses, and advantages and disadvantages to conduct outsourcing in China for biopharmaceutical R&D and manufacturing. It is thus a must-read book to all global pharmaceutical and biopharmaceutical companies that are seeking biopharma outsourcing opportunities in China. It is also a necessary guide to global financial investment companies seeking investment opportunities in the Chinese biopharmaceutical industry. 1

3 Key Findings of the Report As therapeutic biologics have become a new but promising type of medication, the global biopharmaceutical market has been experiencing fast growth in the recent decade. It has been prompting all global major pharma and biopharma companies to increase their investment in biologics. Their R&D strategies have thus been changed dramatically in the recent years. Accompanying the change are their rapidly growing demands for outsourcing services in biologic drug R&D and manufacturing. Attracted by the fast growth of the Chinese biopharmaceutical market and the thriving Chinese biopharmaceutical industry, growing numbers of pharma and biopharma companies large or small around the world have become interested to conduct biologic drug R&D and manufacturing in China in addition to marketing their products in the country. The entrance of these multinational companies and their further expansion in the local market has been prompting them to seek all types of service from local companies to support their local activities. Their demands for various types of supporting services are thus driving up the rapid growth of the biopharmaceutical outsourcing market in China. At almost the same time the Chinese pharma and biopharma companies have also been increasing their investment in both R&D and manufacturing of biologics, largely because of the increasing availabilities of funding opportunities from both public and private sources. To effectively accomplish their development goals, a large portion of them are also seeking service supports from local biopharma outsourcing service providers, thus further driving up the growth of this new Chinese outsourcing market. Consequently, starting from almost nowhere, the Chinese biopharma outsourcing market has been growing extremely fast in the recent couple of years. The current market size of the biologic drug discovery research service in China has reached around $95 M, already accounting for about 5.4% of the corresponding global market. In the past four years ( ) it has been growing in a CAGR about 34%. The current biomanufacturing service market in China is about $170 M with a CAGR of about 24% during It accounts for about 3.5% of the global bio-cmo market. With unprecedented growth in financial power, technological advancements, and biopharmaceutical market, China has been recognized as one of the most potential growth markets in the world. All pharma and biopharma companies around the world would like to capitalize on the growth of the biopharmaceutical research and 2

4 development power in the country, including seeking the opportunities to collaborate/partner with the local organizations in all aspects of biologic drug R&D, manufacturing and marketing. Although still young and limited in their capabilities in both R&D and manufacturing of biologics, Chinese biopharma companies capabilities in these areas are expected to get improved rapidly in the following years, primarily due to the intensive collaborations with the experienced multinational companies. The demands for biopharma outsourcing services in China are also expected to rapidly increase in the coming years by not only the multinational companies but also the domestic pharma and biopharma companies. Biopharmaceutical outsourcing for both R&D and manufacturing is thus expected to be the next wave in the Chinese pharma outsourcing service industry. The Chinese biopharma outsourcing market is thus expected to grow faster in the foreseeable future than in the past. We thus forecast that the Chinese biologic drug discovery research service market will likely grow in a CAGR of 30% during and may reach $450 M by By then it will likely account for about 8% of the global biologic drug discovery research service market. We also forecast that the Chinese biomanufacturing service market will likely grow in a CAGR of also about 30% during the same time period. Its market size could reach around $830 M by 2018, likely accounting for also about 8% of the global bio-cmo market. The combined value of the Chinese biopharma outsourcing market will likely reach around $1.3 B by 2018, accounting for about 8% of the global biopharma outsourcing market by then. 3

5 Key Features of the Report The report is designed to help global pharmaceutical and biopharmaceutical companies better understand the current development state, the available services, and the service capabilities and limitations of the Chinese companies in biologic drug discovery research and biopharmaceutical manufacturing. It also intends to help global financial investment companies and multinational biopharma outsourcing service providers gain clear insights of the future growth potentials of the Chinese biopharma outsourcing market. The report thus first analyzed the current overall development state of the global biopharmaceutical outsourcing industry, including major pharma/biopharma and small biopharma companies outsourcing demands and strategies, the latest outsourcing trends in both biologic drug discovery research and biopharmaceutical manufacturing, and the current sizes and the future growth potentials of the world biopharma outsourcing market in these two sectors. The report also analyzed China s current strengths in biotechnology industry, in particular in biologic drug discovery research and biopharmaceutical manufacturing, and the attractions of the Chinese biopharmaceutical market to the global pharma and biopharma companies, including its current market size and future growth potentials. Meanwhile, the report also analyzed in depth the current service scopes, capabilities and limitations of the Chinese companies, including both drug companies and professional service providers, in both R&D and manufacturing of therapeutic proteins, mabs and peptides. Moreover, the report also discussed in detail the current biopharma outsourcing activities in China of both multinational and domestic companies in biologic drug discovery research and biomanufacturing. More importantly, the report analyzed both the current market sizes and the future growth potentials, including the detailed analysis of all growth drivers and resistors, of the biopharma outsourcing market in China, including the market of biologic drug discovery research service and the market of biopharmaceutical manufacturing service. It is the first time that the report revealed the current strengths and weaknesses of the Chinese companies in biopharmaceutical outsourcing service, and the advantages and disadvantages to conduct biopharma outsourcing in China. The report has thus provided a clear and complete picture of the current competency of the Chinese biopharmaceutical outsourcing service industry. It greatly helps global pharmaceutical and biopharmaceutical companies better gauge the collaboration or partnership opportunities in China with the local counterparts. 4

6 About JZMed, Inc. JZMed, Inc. ( is a leading market research firm specialized in pharmaceutical outsourcing industry. The company s primary focus is to provide intelligence services to global pharmaceutical, biotechnology and investment companies to help them better understand the latest development trends of the global pharmaceutical outsourcing industry so that they are able to formulate their best strategies to tap the industry s resources and opportunities at the best timing. So far JZMed has provided this type of services to a variety of companies worldwide, including world top pharmaceutical and biotechnology companies, professional outsourcing service providers and a large number of investment companies/banks including the largest ones in the Wall Street. 5